Literature DB >> 22858909

Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.

U Bacher, T Haferlach, T Alpermann, W Kern, S Schnittger, C Haferlach.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858909     DOI: 10.1038/leu.2012.200

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

2.  Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.

Authors:  H A Hou; C C Lin; W C Chou; C Y Liu; C Y Chen; J L Tang; Y J Lai; M H Tseng; C F Huang; Y C Chiang; F Y Lee; Y Y Kuo; M C Lee; M C Liu; C W Liu; L I Lin; M Yao; S Y Huang; B S Ko; S C Hsu; S J Wu; W Tsay; Y C Chen; H F Tien
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

3.  Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia.

Authors:  Chin Yuet Meng; Puteri J Noor; Azli Ismail; Mohd Fadly Md Ahid; Zubaidah Zakaria
Journal:  Int J Biomed Sci       Date:  2013-03

4.  The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.

Authors:  Ugo Testa; Elvira Pelosi
Journal:  Leuk Res Treatment       Date:  2013-07-09

5.  Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Authors:  Haven R Garber; Mao Zhang; Gheath Alatrash; Pariya Sukhumalchandra; Yihua Qiu; Haroon Jakher; Alexander A Perakis; Lisa Becker; Suk Young Yoo; Karen C Dwyer; Kevin Coombes; Amjad H Talukder; Lisa S St John; Vladimir Senyukov; Dean A Lee; Anna Sergeeva; Hong He; Qing Ma; Paul M Armistead; Jason Roszik; Elizabeth A Mittendorf; Jeffrey J Molldrem; David Hawke; Gregory Lizee; Steven M Kornblau
Journal:  Leukemia       Date:  2016-08-30       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.